PET Imaging with 124I-PUH71 for Cancer

Recruiting in Palo Alto (17 mi)

Overseen ByMark Dunphy, DO

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body \& inside tumors and how long PUH71 lasts in the blood, when given to study participants in tiny amounts. The results of this study will help researchers (1) plan how they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting tumors with scanner machines.

Eligibility Criteria

This trial is for adults aged 18-90 with certain types of cancer, including solid tumors, myeloma, and lymphomas that can be measured or evaluated. Women must not be pregnant or breastfeeding. Participants should not have had allergic reactions to contrast media, iodide hypersensitivity, hyperthyroidism, significant kidney or liver issues, or acute major illnesses.

Inclusion Criteria

I am not pregnant or unable to become pregnant.

My cancer type has been confirmed by pathology.

I am between 18 and 90 years old.

Exclusion Criteria

I have been diagnosed with an overactive thyroid.

My liver function tests are within the trial's required ranges.

My kidney function is reduced, with creatinine levels high or clearance low.

I do not have any severe illnesses like infections or heart problems.

Participant Groups

Researchers are testing a new drug called PUH71 using PET imaging to see how it distributes in the body and tumors and its duration in the blood. This will inform future high-dose trials for cancer treatment and potential use in tumor detection.

1Treatment groups

Experimental Treatment

Group I: PET Imaging Using 124 IPUH71Experimental Treatment1 Intervention

Patients will receive an injection of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71, followed by serial PET scanning and blood draws, over a period of 3 days. Optional with a fourth day of PET scanning is to be pursued, in willing patients.